MiniMed 780G, the company’s latest-generation AID system, offers meal detection technology and provides automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs.
Data demonstrated rapid, sustained improvements in glycemic control for people living with type 1 diabetes over three years. It also showed the significant reduction in patient burden by automating a growing percentage of insulin delivery over time.
Investigators presented findings at the European Association for the Study of Diabetes (EASD) 61st Annual Meeting in Vienna. The milestones come not long after recent FDA approvals for MiniMed 780G, highlighting the system’s capabilities ahead of the company’s planned separation of the Diabetes unit into a standalone, publicly traded company.
The Medtronic Diabetes Business is one of the largest diabetes tech companies in the world. Learn more about the company and the rest of the diabetes space by downloading our free Diabetes Technology Special Report.
Data came from 1,145 participants aged 16 and older across Europe, the Middle East and Africa (EMEA). Findings highlighted MiniMed 780G’s impact on both clinical outcomes and the daily lives of users.
After initiating system use, patients experienced a rapid increase in time spent within the target glucose range (70-180 mg/dL). The increase reached 78.6% time in range and remained relatively stable throughout the 36-month observation period.
Medtronic reports improved glycemic control and greater automation that created lower patient effort. The average percentage of insulin delivered by autocorrection rose from 0% to 12.9% immediately and grew to 17.2% by year three. User-initiated insulin delivery decreased from 52.4% to 41.5%.
The company also reported a significant increase in the use of recommended optimal system settings (glucose targets of 100 mg/dL and active insulin time of two hours). That indicates rising confidence among users and healthcare providers.
“These findings highlight the significant ability of the MiniMed 780G system to improve diabetes care, providing lasting clinical and lifestyle advantages,” said Dr. Jennifer McVean, senior medical affairs director at Medtronic Diabetes. “As we move closer to fully automated insulin delivery, empowering people with type 1 diabetes to trust and rely on these technologies will be key to achieving better outcomes and improved quality of life.”
